close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Asher Biotherapeutics, Inc.

News headline image
Asher Biotherapeutics Announces Two Presentations at the ASCO 2026 Annual Meeting Highlighting Clinical Progress Across Its CD8-Targeted Cytokine Pipeline
From Asher Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Asher Bio Announces Dosing of First Patient in Phase 1a/1b Clinical Trial of AB248, a Cis-targeted IL-2 Immunotherapy Product Candidate, for the Treatment of Locally Advanced or Metastatic Solid Tumors
From Asher Biotherapeutics, Inc.
Via Business Wire
News headline image
Asher Bio Appoints Independent Director Elaine Sun to Its Board
From Asher Biotherapeutics, Inc.
Via Business Wire
News headline image
Asher Bio Presents New Preclinical Data at ASH Applying Cis-Targeted Cytokines to Enhance CAR-T Cell Therapies
From Asher Biotherapeutics, Inc.
Via Business Wire
News headline image
Asher Bio Presents New Preclinical Data at SITC 2022 Further Supporting Advancement of AB248 and AB821 as Highly Differentiated Cis-targeted Cancer Immunotherapies
From Asher Biotherapeutics, Inc.
Via Business Wire
News headline image
Asher Bio Presents New Data Demonstrating Preclinical Proof-of-Concept for AB359, a Highly Selective CD8-Targeted IL-2 Therapy, for Chronic Hepatitis B (HBV) at AASLD 2022
From Asher Biotherapeutics, Inc.
Via Business Wire
News headline image
Asher Bio to Present New Preclinical Data for Selective Support of CAR-T Cell Therapies by Cis-Targeted IL-2 and IL-21 Cytokines at ASH 2022
From Asher Biotherapeutics, Inc.
Via Business Wire
News headline image
Asher Bio to Present First Preclinical Data for AB359, its CD8-targeted IL-2 Immunotherapy for Hepatitis B at AASLD 2022
From Asher Biotherapeutics, Inc.
Via Business Wire
News headline image
Asher Bio to Present New Preclinical Data for CD8+ T Cell Targeted Immunotherapies, AB248 and AB821, at SITC 2022
From Asher Biotherapeutics, Inc.
Via Business Wire
News headline image
Asher Bio Appoints Independent Director Bob Deresiewicz, M.D., to its Board
From Asher Biotherapeutics, Inc.
Via Business Wire
News headline image
Asher Bio Appoints Andrea Pirzkall, M.D., as Chief Medical Officer
From Asher Biotherapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today